4-Methoxycinnamic Acid

4-Methoxycinnamic Acid

SCHEMBL5653025

CCC(CCCCC(=Cc1ccc(OC)cc1)C(=O)O)C(=O)OCC(O)CO.COc1ccc(C=CC(=O)O)cc1

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.44
ATM Q13315 1/20 0.44
TDP1 Q9NUW8 2/20 0.42
TAS1R3 Q7RTX0 4/20 0.38
TAS1R1 Q7RTX1 4/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
LMNA P02545 2/20 0.37
PPARA Q07869 1/20 0.37
GSK3B P49841 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PTGER4 P35408 1/20 0.35
PTGER3 P43115 1/20 0.35
PTGER2 P43116 1/20 0.35
AKR1C3 P42330 1/20 0.35
AKR1C2 P52895 1/20 0.35
F3 P13726 1/20 0.35
BACE1 P56817 1/20 0.34
TRPM8 Q7Z2W7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
4-Methoxycinnamic Acid SCHEMBL4657863 0.87 TDP1 (0.55) THRBATMTDP1TAS1R3TAS1R1
4-Methoxycinnamic Acid SCHEMBL27805505 0.87 TDP1 (0.55) THRBATMTDP1TAS1R3TAS1R1
4-Methoxycinnamic Acid SCHEMBL344148 0.87 TDP1 (0.55) THRBATMTDP1TAS1R3TAS1R1
4-Methoxycinnamic Acid SCHEMBL4844856 0.81 THRB (0.46) THRBATMTDP1TAS1R3TAS1R1
SCHEMBL7773761 0.79 ALOX5 (0.43) THRBTDP1TAS1R3TAS1R1NPC1
4-Methoxycinnamic Acid SCHEMBL910634 0.78 TDP1 (0.62) THRBATMTDP1TAS1R3TAS1R1
SCHEMBL29203311 0.77 TDP1 (0.58) THRBATMTDP1TAS1R3TAS1R1
Monoctanoin Component A SCHEMBL392377 0.77 KDM4E (0.58) THRBATMTDP1TAS1R3TAS1R1
Octinoxate SCHEMBL6036126 0.76 TDP1 (0.76) TDP1TAS1R3TAS1R1LMNAGSK3B
4-Methoxycinnamic Acid SCHEMBL16333598 0.75 THRB (0.62) THRBATMTDP1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105570-B2 Cysteine derivatives AJINOMOTO CO., INC. (JP) 2006-09-12 US disclosed
US-6703031-B1 OXIDATIVE STRESS INHIBITOR; RETARDING AGING OF SKIN AJINOMOTO CO., INC. (JP) 2004-03-09 US disclosed
US-20030194417-A1 Cysteine derivatives AJINOMOTO CO. INC (JP) 2003-10-16 US disclosed
US-6602492-B2 Cysteine derivatives AJINOMOTO CO., INC. (JP) 2003-08-05 US disclosed
US-20020115723-A1 Cysteine derivatives AJINOMOTO CO., INC. (JP) 2002-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115723-A1 Cysteine derivatives NFE2L2, GCLC, KEAP1 THRB 3075/4885ATM 1674/4885TDP1 2572/4885
US-20030194417-A1 Cysteine derivatives NFE2L2, GCLC, KEAP1 THRB 3075/4885ATM 1674/4885TDP1 2572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.